Market Overview:
The global anticoagulant drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of thrombotic disorders, rising geriatric population, and technological advancements in the field of anticoagulants. The global anticoagulant drugs market is segmented on the basis of type into NOACs, heparin, warfarin, and others. The NOACs segment is expected to grow at a CAGR of 6.1% during the forecast period from 2018 to 2030 due to its high efficacy and safety profile as compared to other types of anticoagulants available in the market. The heparin segment is expected to grow at a CAGR of 4.8% during the same period due its low cost and easy availability across regions.
Product Definition:
An anticoagulant is a drug that interferes with the clotting of blood. They are used to prevent thrombosis (clotting within the vessels) and pulmonary embolism (clotting in the lungs).
NOACs:
Anticoagulant drugs are used to prevent blood clotting and to treat the existing blood clots. The global anticoagulant market is expected to witness significant growth over the forecast period owing to increasing incidences of lifestyle diseases such as diabetes, obesity, and high cholesterol levels. In addition, growing geriatric population base coupled with rising demand for home healthcare services is also anticipated to drive the market during the forecast period.
Heparin:
Heparin is a type of anticoagulant drug used to prevent blood clotting. It works by blocking the thrombus (clot) formation and prevents the patient from bleeding. Heparin has no effect on healthy cells and only inhibits blood clotting in patients suffering from diseases such as atrial fibrillation, coronary artery disease, deep vein thrombosis, etc.
Application Insights:
The application segment includes hospital, pharmacy and others. The other applications include industrial use, oral anticoagulants and internal bleeding. In 2017, the hospital accounted for the largest share in terms of revenue as well as volume in the global anticoagulant drugs market. This is due to factors such as increasing number of patients suffering from stroke or heart attack across all age groups which has resulted in a high demand for blood thinner medications that are used to prevent blood clots from forming within the arteries.
Pharmacy is expected to be one of fastest growing segments over forecast period owing to factors such as rising geriatric population base globally which increases risk of thrombosis and availability of generic warfarin tablets & capsules that are cheaper than their brand-name counterparts thereby making it affordable for most patients seeking treatment at pharmacies rather than hospitals.
Regional Analysis:
North America dominated the global anticoagulant drugs market in 2017. The presence of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some of the major factors responsible for its large share. In addition, growing R&D activities to develop novel products is expected to fuel the regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China & India & South Korea & Indonesia etc., which will result into an increase in drug consumption over next eight years (2018-2030). Moreover, economic development coupled with government initiatives aimed at reducing treatment costs may further boost revenue generation from this region.
Growth Factors:
- Increasing incidence of thrombotic disorders: The global anticoagulant drugs market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of thrombotic disorders such as deep vein thrombosis (DVT), pulmonary embolism, and myocardial infarction.
- Growing geriatric population: The global anticoagulant drugs market is also driven by the growing geriatric population, as this population is more susceptible to developing thrombotic disorders.
- Technological advancements in anticoagulant drugs: The development of novel oral anticoagulants (NOACs) has revolutionized the treatment landscape for patients with venous and arterial thromboembolic diseases, which is driving the growth of the global anticoagulant drugs market. These novel agents are safer and more efficacious than traditional warfarin therapy and are becoming first-line therapies for a number of indications such as DVT, stroke prevention in atrial fibrillation (AF), and acute coronary syndrome (ACS). In addition, there has been an increase in approvals for NOACs over traditional vitamin K antagonists (VKAs) in recent years owing to their better safety profile and efficacy profiles across different patient populations including elderly patients with renal impairment or those taking multiple medications concurrently. This is likely to further boost demand for NOACs over
Scope Of The Report
Report Attributes
Report Details
Report Title
Anticoagulant Drugs Market Research Report
By Type
NOACs, Heparin, Warfarin, Others
By Application
Hospital, Pharmacy, Others
By Companies
Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Anticoagulant Drugs Market Report Segments:
The global Anticoagulant Drugs market is segmented on the basis of:
Types
NOACs, Heparin, Warfarin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Bayer
- Pfizer
- Johnson & Johnson
- Sanofi
- Boehringer Ingelheim
- Daiichi Sankyo
Highlights of The Anticoagulant Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NOACs
- Heparin
- Warfarin
- Others
- By Application:
- Hospital
- Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anticoagulant Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anticoagulant drugs are medications that help to prevent blood from clotting. They can be used to treat a variety of conditions, including stroke, heart attack, and pulmonary embolism.
Some of the key players operating in the anticoagulant drugs market are Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo.
The anticoagulant drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anticoagulant Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anticoagulant Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anticoagulant Drugs Market - Supply Chain
4.5. Global Anticoagulant Drugs Market Forecast
4.5.1. Anticoagulant Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anticoagulant Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anticoagulant Drugs Market Absolute $ Opportunity
5. Global Anticoagulant Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anticoagulant Drugs Market Size and Volume Forecast by Type
5.3.1. NOACs
5.3.2. Heparin
5.3.3. Warfarin
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anticoagulant Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anticoagulant Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Pharmacy
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anticoagulant Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anticoagulant Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anticoagulant Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anticoagulant Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anticoagulant Drugs Demand Share Forecast, 2019-2026
9. North America Anticoagulant Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anticoagulant Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anticoagulant Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Pharmacy
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anticoagulant Drugs Market Size and Volume Forecast by Type
9.7.1. NOACs
9.7.2. Heparin
9.7.3. Warfarin
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anticoagulant Drugs Demand Share Forecast, 2019-2026
10. Latin America Anticoagulant Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anticoagulant Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anticoagulant Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Pharmacy
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anticoagulant Drugs Market Size and Volume Forecast by Type
10.7.1. NOACs
10.7.2. Heparin
10.7.3. Warfarin
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anticoagulant Drugs Demand Share Forecast, 2019-2026
11. Europe Anticoagulant Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anticoagulant Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anticoagulant Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Pharmacy
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anticoagulant Drugs Market Size and Volume Forecast by Type
11.7.1. NOACs
11.7.2. Heparin
11.7.3. Warfarin
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anticoagulant Drugs Demand Share, 2019-2026
12. Asia Pacific Anticoagulant Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anticoagulant Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anticoagulant Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Pharmacy
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anticoagulant Drugs Market Size and Volume Forecast by Type
12.7.1. NOACs
12.7.2. Heparin
12.7.3. Warfarin
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anticoagulant Drugs Demand Share, 2019-2026
13. Middle East & Africa Anticoagulant Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anticoagulant Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anticoagulant Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Pharmacy
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anticoagulant Drugs Market Size and Volume Forecast by Type
13.7.1. NOACs
13.7.2. Heparin
13.7.3. Warfarin
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anticoagulant Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anticoagulant Drugs Market: Market Share Analysis
14.2. Anticoagulant Drugs Distributors and Customers
14.3. Anticoagulant Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Boehringer Ingelheim
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Daiichi Sankyo
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
